在阿尔茨海默病中与血管粉样蛋白-β的联合聚合物
Jessica Wagner1,2,3, Karoline Degenhardt1,2,3, Marleen Veit1,2,3
1German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Nature
|November 17, 2022
概括
在老年人中常见的梅丁粉素会恶化脑血管功能障碍. 梅丁与β-氨基酸相互作用,促进其聚合,并可能作为认知衰退的治疗点.
科学领域:
- 神经科学
- 生物化学
- 老年学
背景情况:
- 在老年人血管中,梅丁粉聚物很常见.
- 脑血管功能失调的原因.
- 梅丁是一种MFG-E8 (乳腺素) 的片段.
研究的目的:
- 研究梅丁与阿尔茨海默病中的血管粉蛋白-β沉积之间的关系.
- 确定梅丁在促进粉样β聚合中的作用.
- 探索医学作为潜在的治疗目标.
主要方法:
- 研究了粉样蛋白前体 (APP) 转基因小鼠和阿尔茨海默病患者.
- 在大脑血管中分析了美丁和β-粉素的同定位.
- 评估了梅丁缺乏对小鼠粉样β沉积的影响.
- 测量MFG-E8和麦丁水平与血管粉素-β负担相关.
- 分析了MFGE8表达和认知衰退的ROSMAP队列数据.
- 在体外和体内研究的美丁-粉素-β相互作用.
主要成果:
- 在APP转基因小鼠和阿尔茨海默病患者中,Medin与血管中的β-氨基酸沉积物共定位.
- 在小鼠中,梅丁缺乏减少了50%的血管粉素β沉积.
- 随着血管β粉样蛋白负荷的严重程度,MFG-E8和美丁水平的增加.
- 在阿尔茨海默病患者中,高MFGE8表达与认知衰退相关,独立于斑块和tau.
- 梅丁与β粉样蛋白直接相互作用,促进其聚合并改变纤维结构.
结论:
- 梅丁聚合与血管粉样β沉积和认知衰退密切相关.
- 梅丁直接促进粉样β聚合,形成异质纤维.
- 梅丁是一种潜在的治疗点,可以预防与β粉样蛋白沉积相关的血管损伤和认知衰退.
更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.7K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
相关概念视频
Amyloid Fibrils
9.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Overview
621
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
621
